Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-222-8041
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.76 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions
What is Apricus Biosciences' stock symbol?
Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."
How were Apricus Biosciences' earnings last quarter?
Apricus Biosciences Inc (NASDAQ:APRI) released its earnings results on Wednesday, October, 31st. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.02. View Apricus Biosciences' Earnings History.
Has Apricus Biosciences been receiving favorable news coverage?
Media coverage about APRI stock has trended somewhat positive this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Apricus Biosciences earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the next several days.
Who are some of Apricus Biosciences' key competitors?
Some companies that are related to Apricus Biosciences include AC Immune (ACIU), Beyondspring (BYSI), Neptune Wellness Solutions (NEPT), Insys Therapeutics (INSY), BIOFRONTERA AG/ADR (BFRA), Constellation Pharmaceuticals (CNST), PhaseBio Pharmaceuticals (PHAS), AcelRx Pharmaceuticals (ACRX), MannKind (MNKD), Karyopharm Therapeutics (KPTI), Seres Therapeutics (MCRB), Minerva Neurosciences (NERV), Immune Design (IMDZ), Lannett (LCI) and Kadmon (KDMN).
What other stocks do shareholders of Apricus Biosciences own?
Who are Apricus Biosciences' key executives?
Apricus Biosciences' management team includes the folowing people:
- Mr. Richard W. Pascoe, CEO, CFO, Sec., Principal Accounting Officer & Director (Age 55)
- Mr. Neil C. Morton, Sr. VP & Chief Bus. Officer (Age 43)
- Mr. Brian T. Dorsey, Consultant (Age 50)
- Ms. Kelly Deck, Exec. Director of Fin.
- Ms. Mary Naggs, VP & Gen. Counsel
How big of a company is Apricus Biosciences?
Apricus Biosciences has a market capitalization of $0.00 and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.
What is Apricus Biosciences' official website?
How can I contact Apricus Biosciences?
Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]
MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
